Skip to main content
NPCE logo

NPCE · NeuroPace Inc · Investor Relations

Track NPCE — free
$8.50 +0.53 (+6.59%) Play latest call Q3 2026 earnings call transcript
Market Cap
$274.58M
Shares
34.45M
Volume · Nov 17 163.06K Avg daily vol (3M) 246.14K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-12 NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
2026-10-29 NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-09-01 NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
2026-08-31 NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
2026-08-11 NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
2026-07-28 NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
2026-05-29 NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
2026-05-29 NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
2026-05-12 NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
2026-04-29 NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
2026-04-27 NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
2026-04-10 NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-03-05 NeuroPace to Present at the Leerink Global Healthcare Conference
2026-03-03 NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
2026-02-20 NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
2026-01-13 NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Past events

Source: https://investors.neuropace.com/overview/default.aspx

Key facts CIK 1528287 CUSIP 641288105 13F (30d) 115 filings 100 filers Visit website Investor relations